Posters presented at the 2026 AAD Annual Meeting examined bimekizumab for hidradenitis suppurative across various subgroups ...
Please provide your email address to receive an email when new articles are posted on . Patients treated by dermatologists vs. non-dermatologists were much more likely to be prescribed biologics (19.7 ...
Povorcitinib, an oral JAK-1 inhibitor currently being investigated for hidradenitis suppurativa, demonstrated substantial ...
Incyte’s phase 3 STOP-HS data show that povorcitinib improved symptoms of moderate to severe hidradenitis suppurativa in most ...
Patients with HS who smoke had more severe disease and worse response to treatment with tetracycline-class agents than nonsmokers.
Add Yahoo as a preferred source to see more of our stories on Google. To begin with the basics, hidradenitis suppurativa is a skin disease that experts think originates with an overactive immune ...
There’s an added layer of complexity if you’re a person of color. Black women, in particular, have a higher risk of HS. While anyone can develop darker areas after their skin is damaged or ...
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 ...
Maybe it’s that new exercise program you’ve been following. Or maybe you just sweat a lot. Whatever the reason, you’ve noticed a bunch of red bumps on your skin lately, especially in the folds of your ...
HS Often Misdiagnosed – Hidradenitis Suppurativa (HS) affects 1 in 100 people, especially Black women, but is frequently mistaken for other skin conditions. Early Diagnosis is Key – Delayed treatment ...
Hidradenitis suppurativa (HS) is a complicated condition that’s easily confused for other skin issues, like acne or boils, so it can be tough to get an accurate diagnosis the first time you see a ...
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual ...